← Back to all trials
Recruiting
NCT06531798
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
Conditions: Moderate to Severe COPD
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 150
Sponsor: AstraZeneca
Location: Research Site Dalgate, Drugjan
Summary
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
Eligibility Criteria
Inclusion Criteria:
Patients with a physician-confirmed diagnosis of COPD
* With a history of one severe COPD exacerbation or two or more moderate COPD exacerbations in the preceding 12 months.
* Post-bronchodilator FEV1 should be between ≥30 % to \
Source: ClinicalTrials.gov (NCT06531798). StuddyBuddy aggregates publicly available trial information.
